In a Phase 1a escalating clinical trial, autologous mesenchymal stem cell infusion for renovascular disease increases blood flow and the glomerular filtration rate while reducing inflammatory biomarkers and blood pressure

著者: Abdelrhman Abumoawad, Ahmed Saad, Christopher M. Ferguson, Alfonso Eirin, Sandra M. Herrmann, LaTonya J. Hickson, Busra B. Goksu, Emily C. Bendel, Sanjay Misra, James F. Glockner, Allan B. Dietz, Lilach O. Lerman, Stephen C. Textor - Kidney International 2019 被引用: 102